Drug intelligence / Profile preview

ABF-101 + ABF-103

Development stage: Preclinical
Lead developer: Aptabio Therapeutics
Modality: Small Molecules
Administration: Oral, Ophthalmic

Overview

ABF-101 and ABF-103 are small molecule inhibitors of NADPH oxidase (NOX) enzymes developed by Aptabio Therapeutics for the treatment of wet age-related macular degeneration (wet-AMD). These compounds are designed to modulate oxidative stress, a key driver in the pathogenesis of retinal diseases and pathological angiogenesis. ABF-101 is formulated for oral administration, whereas ABF-103 is developed as a topical eye drop. By inhibiting NOX enzymes, which are primary sources of reactive oxygen species (ROS), these therapeutic candidates aim to reduce oxidative damage and neovascularization in the eye. Both programs are currently in preclinical development.

Other names: ABF-101/103

Targets

NOX4 (NADPH oxidase 4)

Beyond the preview

Go deeper on ABF-101 + ABF-103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABF-101 + ABF-103.

Explore the full profile